Results 61 to 70 of about 181,087 (306)

Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity

Signal Transduction and Targeted Therapy, 2023
Ligand-induced receptor dimerization or oligomerization is a widespread mechanism for ensuring communication specificity, safeguarding receptor activation, and facilitating amplification of signal transduction across the cellular membrane.
Yan Sun, Xiu-Na Yang, Shuang-Shuang Yang, Yi-Zhu Lyu, Bing Zhang, Kai-Wen Liu, Na Li, Jia-Chen Cui, Guang-Xiang Huang, Cheng-Lin Liu, Jie Xu, Jian-Qing Mi, Zhu Chen, Xiao-Hu Fan, Sai-Juan Chen, Shuo Chen   +15 more
doaj   +1 more source

New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer [PDF]

, 2012
A summit on cellular therapy for cancer discussed and presented advances related to the use of adoptive cellular therapy for melanoma and other cancers. The summit revealed that this field is advancing rapidly.
A Lundqvist, A Somers, C Berger, CA Tran, Carolina Berger, Cornelis JM Melief, Daniel J Powell, David F Stroncek, DG Song, DJ Powell Jr, DL Porter, Francesco M Marincola, G Mostoslavsky, GG Kenter, Gustavo Mostoslavsky, J Jin, J Staerk, James R Heath, Jeffrey S Miller, JN Kochenderfer, JN Kochenderfer, John O'Shea, JS Miller, K Takahashi, L Gattinoni, L Gattinoni, L Gattinoni, L Gattinoni, LA Johnson, Luca Gattinoni, M Kalos, M Kalos, M Kalos, Mahendra Rao, Mark E Dudley, Martin A Cheever, ME Dudley, ME Dudley, Michael Kalos, Nicholas P Restifo, P Muranski, Peter Flynn, PF Robbins, RA Morgan, Richard W Childs, SA Rosenberg, Steven A Rosenberg, TS Park, X Wang   +48 more
core   +4 more sources

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Tumor site-directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors

Nature Communications
The efficacy of Chimeric Antigen Receptor T cells against solid tumors is limited by immunosuppressive factors in the tumor microenvironment including adenosine, which suppresses Chimeric Antigen Receptor T cells through activation of the A2A receptor ...
Kevin Sek, Amanda X. Y. Chen, Thomas Cole, Jesse D. Armitage, Junming Tong, Kah Min Yap, Isabelle Munoz, Phoebe A. Dunbar, Shiyi Wu, Marit J. van Elsas, Olivia Hidajat, Christina Scheffler, Lauren Giuffrida, Melissa A. Henderson, Deborah Meyran, Fernando Souza-Fonseca-Guimaraes, Dat Nguyen, Yu-Kuan Huang, Maria N. de Menezes, Emily B. Derrick, Cheok Weng Chan, Kirsten L. Todd, Jack D. Chan, Jasmine Li, Junyun Lai, Emma V. Petley, Sherly Mardiana, Anthony Bosco, Jason Waithman, Ian A. Parish, Christina Mølck, Gregory D. Stewart, Lev Kats, Imran G. House, Phillip K. Darcy, Paul A. Beavis   +35 more
doaj   +1 more source

T cell receptor-engineered T cells for leukemia immunotherapy

Cancer Cell International, 2019
At present, refractory and relapse are major issues for leukemia therapy and a major cause of allogeneic hematopoietic stem cell transplant failure. Over the last decade, many studies have demonstrated that adoptive cancer antigen-specific T cell therapy
Yikai Zhang, Yangqiu Li
doaj   +1 more source

Novel Cell type-specific aptamer-siRNA delivery system for HIV-1 therapy [PDF]

, 2007
The successful use of small interfering RNAs (siRNAs) for therapeutic purposes requires safe and efficient delivery to specific cells and tissues. Here we demonstrate cell type-specific delivery of anti-HIV siRNAs via fusion to an anti-gp120 aptamer. The
Haitang Li, Jiehua Zhou, John Rossi, John Zaia, Shirley Li   +4 more
core   +2 more sources

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Therapeutic applications of engineered chimeric antigen receptors-T cell for cancer therapy

Beni-Suef University Journal of Basic and Applied Sciences, 2022
Background Findings of new targeted treatments with adequate safety evaluations are essential for better cancer cures and mortality rates. Immunotherapy holds promise for patients with relapsed disease, with the ability to elicit long-term remissions ...
Amina Hussain
doaj   +1 more source

Chimeric Antigen Receptors Expand the Repertoire of Antigenic Macromolecules for Cellular Immunity

Cells, 2021
T-cell therapies have made significant improvements in cancer treatment over the last decade. One cellular therapy utilizing T-cells involves the use of a chimeric MHC-independent antigen-recognition receptor, typically referred to as a chimeric antigen ...
John T. Keane, Avery D. Posey
doaj   +1 more source

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia [PDF]

, 2019
The majority of adult patients affected by B-cell acute lymphoblastic leukemia (B-ALL) will relapse after an initial response, while approximately 20% will display primary resistant disease. Patients suffering from relapsed/refractory B-ALL have a very
Lanza, Francesco, Maffini, Enrico, Saraceni, Francesco   +2 more
core   +1 more source